Good news. The FDA granted fast track designation for a mRNA vaccine candidate (ARCT-2304) for active immunization to protect against influenza A H5N1 subtype, or bird flu. The vaccine is still in phase 1 clinical trials, but interim data is expected in the second half of 2025
https://www.drugtopics.com/view/fda-grants-fast-track-designation-for-potential-bird-flu-vaccine #press #birdflu
https://www.drugtopics.com/view/fda-grants-fast-track-designation-for-potential-bird-flu-vaccine #press #birdflu
FDA Grants Fast Track Designation for Potential Bird Flu Vaccine
The designation addresses the unmet need for prevention of H5N1, which remains a global health risk, and a phase 1 trial of the vaccine was initiated in November 2024.Ashley Gallagher (Drug Topics)
